Bispecific antibodies (bsAb) are emerging as an important class of therapeutics. Bispecific antibodies have increased potential for precision targeting and higher potency. Multi antigen binding can help reduce the development of subsequent clinical resistance. Different strategies have been used in the past to create bsAbs. However, key challenges remain with the development of bispecific antibodies, including:
- Highly engineered formats that least resemble native proteins could have a higher risk of unwanted immunogenicity
- Expression of two different heavy and light chains in a single cell can create misassembled unwanted species. These impurities can be difficult to remove due to their similarity to the correct format
Lonza’s bYlok® bispecific antibody platform was developed keeping in mind the evolving needs of antibody-drug developers. The simplicity of application is within the design itself. It provides an engineering solution for bispecific antibodies where two different light chains are needed, supporting streamlined bispecific antibody development.
By moving the disulphide bridge from constant domains (CH1/CL) to variable domains (VH/VL), the formation of HC-LC heterodimers is favored. The modifications add minimal changes to the molecule’s natural design to minimize unwanted immune responses and support excellent manufacturability.
Access bYlok® for your bispecific antibody design. A precision pairing technology that links partners to better possibilities
Access to our bYlok® technology platform is easy. The technology is available via a simple research license to see if it fits your processes and bispecific antibody production strategy.
Talk to our experts to get to know more about the Lonza in Your Lab® offering and bYlok® technology platform.
Ask the Experts in Expression
The bYlok® bispecific antibody platform is Lonza’s precision engineered technology designed to support efficient development of bispecific antibodies. It enables >95% correct heavychain/lightchain pairing, providing an IgGlike bispecific format that closely resembles natural antibodies while simplifying downstream production and manufacturability.
Yes. The bYlok® platform is highly versatile and compatible with a wide range of bispecific antibody formats. Its engineering strategy allows developers to incorporate two different light chains with high fidelity, making it suitable for IgG like bispecifics and other emerging therapeutic designs requiring precise chain pairing.
Accessing the bYlok® bispecific antibody platform is straightforward. Developers can obtain the technology through a simple research license, allowing them to evaluate its fit for their bispecific antibody development and production strategies. Lonza also provides expert support to help integrate the bYlok® platform into existing workflows.
Sign up. Stay up-to-date.